{"context":{"query":">>hgnc>>gwas","source_dataset":"hgnc","target_dataset":"gwas"},"stats":{"queried":1,"total":30,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|mapped_gene|chr_id|p_value","mappings":[{"input":"HGNC:18618","source":"HGNC:18618|leucine rich repeat kinase 2","targets":["GCST000207_16|Crohn's disease|LRRK2, LRRK2-DT, LINC02471|12|3.000000e-10","GCST000530_3|Parkinson's disease|SLC2A13|12|3.000000e-08","GCST000879_43|Crohn's disease|MUC19|12|6.000000e-21","GCST000959_3|Parkinson's disease|LRRK2|12|6.000000e-14","GCST001126_8|Parkinson's disease|LRRK2|12|2.000000e-28","GCST001445_1|Parkinson's disease|LRRK2|12|3.000000e-21","GCST001445_2|Parkinson's disease|LRRK2|12|6.000000e-15","GCST001725_24|Inflammatory bowel disease|MUC19|12|6.000000e-29","GCST001762_849|Obesity-related traits|LRRK2 - MUC19|12|5.000000e-06","GCST002455_1|Parkinson's disease|CNTN1|12|2.000000e-27","GCST002544_25|Parkinson's disease|LRRK2-DT, LRRK2|12|5.000000e-14","GCST002772_20|Leprosy|SLC2A13|12|2.000000e-07","GCST003074_9|Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)|MUC19 - CNTN1|12|9.000000e-08","GCST003097_24|Pediatric autoimmune diseases|LRRK2|12|3.000000e-10","GCST003518_9|Daytime sleep phenotypes|LRRK2|12|8.000000e-07","GCST003922_3|Parkinson's disease|SLC2A13|12|8.000000e-12","GCST003984_6|Parkinson's disease|LRRK2|12|1.000000e-39","GCST004131_46|Inflammatory bowel disease|LRRK2|12|3.000000e-15","GCST004132_74|Crohn's disease|LRRK2|12|6.000000e-20","GCST004902_5|Parkinson's disease|LRRK2-DT, LRRK2|12|1.000000e-19","GCST005537_68|Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)|LRRK2|12|4.000000e-17","GCST009325_36|Parkinson's disease or first degree relation to individual with Parkinson's disease|LRRK2-DT, LRRK2|12|2.000000e-28","GCST009325_37|Parkinson's disease or first degree relation to individual with Parkinson's disease|LRRK2|12|4.000000e-148","GCST009325_98|Parkinson's disease or first degree relation to individual with Parkinson's disease|MUC19|12|2.000000e-20","GCST009512_2|Parkinson's disease|LRRK2 - MUC19|12|7.000000e-11","GCST010204_118|Low density lipoprotein cholesterol levels|SLC2A13 - LINC02555|12|2.000000e-09","GCST90002395_361|Mean platelet volume|LINC02471, LRRK2-DT, LRRK2|12|3.000000e-12","GCST90002400_400|Plateletcrit|LRRK2|12|4.000000e-13","GCST90002401_412|Platelet distribution width|LRRK2|12|3.000000e-11","GCST90002402_115|Platelet count|LRRK2|12|1.000000e-20"]}]}